Should You Retain Henry Schein Stock in Your Portfolio Right Now?

Henry Schein (HSIC) faces macroeconomic headwinds and tough competition despite the strong growth of its Henry Schein One joint venture and its widespread global network. The company's dental software business, including Dentrix Ascend and Dentally, is performing well, with nearly 20% year-over-year growth in subscribers, and the company beat earnings estimates in the last four quarters; however, cost of sales increased in the first quarter, impacting gross profit and margin, and the stock has underperformed the S&P 500 over the past year.

Analysis

Henry Schein (HSIC) presents a nuanced outlook, with its Henry Schein One joint venture serving as a significant growth engine, particularly through its dental software solutions like Dentrix Ascend and Dentally, which have seen subscriber numbers grow nearly 20% year-over-year to over 9,500. The company is actively expanding its offerings, evidenced by the acquisition of R. Weinstein, Inc. to bolster its Hawaiian presence and the development of new solutions such as the axiUm Engage platform and Adlumin MDR cybersecurity service. Despite consistently beating earnings estimates for four trailing quarters with an average surprise of 2.40%, and a slight upward revision in the 2025 EPS consensus estimate to $4.87 (a 0.6% increase), the stock has underperformed the broader market, declining 0.1% in the past year compared to the S&P 500's 9.3% gain, though it fared slightly better than its industry's 1% decline. This underperformance reflects prevailing headwinds, including macroeconomic challenges such as inflation and exchange rate fluctuations, which contributed to a 0.4% rise in Q1 cost of sales, a 1.2% decrease in gross profit, and a 34 basis point contraction in gross margin. Furthermore, Henry Schein operates in a highly competitive U.S. healthcare distribution market and faces intense competition in the animal health sector and overseas, potentially pressuring market share and profitability. The projected 2.3% revenue growth to $12.96 billion for 2025 indicates modest top-line expansion.

Key Decisions for Investors

• Investors should closely monitor Henry Schein's ability to manage its rising cost of sales and protect gross margins, particularly given the 34 basis point contraction in the first quarter, alongside the sustained growth momentum within its Henry Schein One technology segment.
• Given the stock's 0.1% decline over the past year, underperforming the S&P 500, and its Zacks Rank #3 (Hold) status, a neutral stance may be appropriate, pending further evidence of successful mitigation of macroeconomic headwinds and competitive pressures.
• Attention should be paid to the execution and market reception of new initiatives such as the axiUm Engage platform and Adlumin MDR cybersecurity solution, as these could offset challenges and drive future growth despite the tough competitive landscape and modest overall revenue growth projections.